Kadono Y, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kamijima T, et al. Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST. Urol J [Internet]. 2021 Dec. 20 [cited 2026 Jul. 8];19(03):202-8. Available from: https://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/6652